At ASCO, Astra Zeneca reported that its drug Enhertu stalled the growth of tumors by more than a year in women with the most common form of metastatic breast cancer.

References: Enhertu® (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease ...

Enhertu has been called a breakthrough in breast cancer treatment. While it doesn’t cure HER2 breast cancer, research shows that it provides patients with more time. According to the National Library ...